357 related articles for article (PubMed ID: 21971008)
21. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
Fernandez HH; Chen JJ
Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937
[TBL] [Abstract][Full Text] [Related]
22. The evaluation of N-propargylamine-2-aminotetralin as an inhibitor of monoamine oxidase.
Meiring L; Petzer JP; Legoabe LJ; Petzer A
Bioorg Med Chem Lett; 2022 Jul; 67():128746. PubMed ID: 35447344
[TBL] [Abstract][Full Text] [Related]
23. Tyramine and irreversible monoamine oxidase inhibitors in clinical practice.
Cooper AJ
Br J Psychiatry Suppl; 1989 Oct; (6):38-45. PubMed ID: 2695126
[TBL] [Abstract][Full Text] [Related]
24. Selegiline ameliorates depression-like behaviors in rodents and modulates hippocampal dopaminergic transmission and synaptic plasticity.
Ishikawa T; Okano M; Minami A; Tsunekawa H; Satoyoshi H; Tsukamoto Y; Takahata K; Muraoka S
Behav Brain Res; 2019 Feb; 359():353-361. PubMed ID: 30359642
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy.
Löscher W; Lehmann H; Teschendorf HJ; Traut M; Gross G
J Pharmacol Exp Ther; 1999 Mar; 288(3):984-92. PubMed ID: 10027835
[TBL] [Abstract][Full Text] [Related]
26. Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms.
Naoi M; Maruyama W; Inaba-Hasegawa K
Expert Rev Neurother; 2013 Jun; 13(6):671-84. PubMed ID: 23739004
[TBL] [Abstract][Full Text] [Related]
27. Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease?
Tabakman R; Lecht S; Lazarovici P
Bioessays; 2004 Jan; 26(1):80-90. PubMed ID: 14696044
[TBL] [Abstract][Full Text] [Related]
28. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.
deMarcaida JA; Schwid SR; White WB; Blindauer K; Fahn S; Kieburtz K; Stern M; Shoulson I; ;
Mov Disord; 2006 Oct; 21(10):1716-21. PubMed ID: 16856145
[TBL] [Abstract][Full Text] [Related]
29. The inhibition of tyramine oxidation and the tyramine hypertensive response ("cheese effect") may be independent phenomena.
Sandler M; Glover V; Ashford A; Esmail A
J Neural Transm; 1980; 48(4):241-7. PubMed ID: 6775051
[TBL] [Abstract][Full Text] [Related]
30. MAO-B inhibitors for the treatment of Parkinson's disease.
Mov Disord; 2002; 17 Suppl 4():S38-44. PubMed ID: 12211138
[No Abstract] [Full Text] [Related]
31. Molecular Mechanism and Structure-activity Relationship of the Inhibition Effect between Monoamine Oxidase and Selegiline Analogues.
Yang C; Wang X; Gao C; Liu Y; Ma Z; Zang J; Wang H; Liu L; Liu Y; Sun H; Wang W
Curr Comput Aided Drug Des; 2024; 20(5):474-485. PubMed ID: 37138424
[TBL] [Abstract][Full Text] [Related]
32. [On the role of MAO B inhibitors and NMDA antagonists in the therapy of Parkinson's disease].
Kassubek J; Büttner T; Reichmann H; Riederer P; Schulz JB; Wüllner U; Csoti I
Fortschr Neurol Psychiatr; 2010 Mar; 78 Suppl 1():S34-6. PubMed ID: 20195940
[TBL] [Abstract][Full Text] [Related]
33. Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease.
Chen JJ; Ly AV
Am J Health Syst Pharm; 2006 May; 63(10):915-28. PubMed ID: 16675649
[TBL] [Abstract][Full Text] [Related]
34. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition.
Clarke A; Johnson ES; Mallard N; Corn TH; Johnston A; Boyce M; Warrington S; MacMahon DG
J Neural Transm (Vienna); 2003 Nov; 110(11):1257-71. PubMed ID: 14628190
[TBL] [Abstract][Full Text] [Related]
35. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
Knoll J
Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
[TBL] [Abstract][Full Text] [Related]
36. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
Fernandez HH; Chen JJ
Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
[TBL] [Abstract][Full Text] [Related]
37. A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease.
Youdim MB; Riederer PF
Neurology; 2004 Oct; 63(7 Suppl 2):S32-5. PubMed ID: 15477584
[No Abstract] [Full Text] [Related]
38. Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat.
Finberg JP; Youdim MB
Br J Pharmacol; 1985 Jun; 85(2):541-6. PubMed ID: 3928010
[TBL] [Abstract][Full Text] [Related]
39. Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline.
Abassi ZA; Binah O; Youdim MB
Br J Pharmacol; 2004 Oct; 143(3):371-8. PubMed ID: 15339864
[TBL] [Abstract][Full Text] [Related]
40. Clinical pharmacology of MAO inhibitors: safety and future.
Yamada M; Yasuhara H
Neurotoxicology; 2004 Jan; 25(1-2):215-21. PubMed ID: 14697896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
